European Psychiatry - Volume 41

S760

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S710–S771

they either have a more favorable SD profile. (3) SD with vortiox-

etine was not statistically higher when compared with placebo,

and was statistically lower compared with other SSRIs or SNRIs.

(4) There is evidence that antidepressants that are also 5–HT1A

receptor agonists (e.g. vortioxetine and vilazodone) may facilitate

sexual performance.

Conclusions

In case of SD pharmacologic and non-pharmacologic

options are available. Vortioxetine seems to be a good pharmaco-

logic option, with better NNH than SNRI and less SD.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2017.01.1425

EV1096

Aripiprazole once monthly outpatient

experience

P. Sánchez Páez

∗

, J.L. Gómez Cano , L. Sánchez Flores ,

R. González Lucas , P. Artieda Urrutia

Hospital Ramón y Cajal, Psychiatry, Madrid, Spain

∗

Corresponding author.

Introduction

Aripiprazole oncemonthly (AOM) is one of themost

recently introduced antipsychotics with a different mechanism of

action, which seems to bring clinical and tolerability implications

[1] .

Objectives

We describe the patient profile that may benefit from

AOM treatment.

Methods

This is a single-centre, retrospective, one year follow-

up study of 13 cases of ambulatory AOM use. We analyze clinical

and functional evolution, and the tolerability profile of patients in

a real clinical practice basis.

Results

Mean age was 53.69; 53.8% were males and 46.2%

females. The most frequent diagnosis was Schizophrenia and other

chronic psychosis (69.3%). Only 7.7% had co-morbidity with sub-

stance use disorder (cocaine); 61.6% were on previous treatment

with other injectable anti-psychotics; 84,6% of the sample received

AOM as monotherapy. Reasons for switching to AOM are shown on

Fig. 1 . E

vents during switching are shown on

Fig. 2 . O

utcomes with

AOM long-term treatment were positive in 84.61% of cases and are

shown on

Fig. 3 .

Conclusions

Switching to AOM could be considered as a good

strategy to improve tolerability, functionality andultimately adher-

ence to treatment in patients in middle age of life with a chronic

psychotic disorder

[2] .

Fig. 1

Reasons for switching.

Fig. 2

Events during switching.

Fig. 3

Outcomes with AOM.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

References

[1] Kane J, Peters-Strickland T, Ross A, et al. Aripiprazole once-

monthly in the acute treatment of schizophrenia: findings

from a 12-week, randomized, double-blind, placebo-controlled

study. J Clin Psychiatry 2014;75(11):1254–60.

[2] Fagiolini A, Brugnoli R, Di Sciascio G, et al. Switching

antipsychotic medication to aripiprazole: position paper by

a panel of Italian psychiatrists. Expert Opin Pharmacother

2015;16(5):727–37.

http://dx.doi.org/10.1016/j.eurpsy.2017.01.1426

EV1097

Clinical vignette – Aripiprazol long

acting injection monotherapy as

long-term treatment for bipolar

disease

C. Solana

∗

, S. Nascimento , M. Duarte , M. Mendes

Centro Hospitalar Psiquiatrico de Lisboa, Psychiatry, Lisboa, Portugal

∗

Corresponding author.

Introduction

Over the last decade a number of effective mainte-

nance treatments for bipolar disorder (BPD) have been developed.

Lithium remains the best-established option, but valproic acid,

lamotrigine, olanzapine, and quetiapine are also effective main-

tenance drugs. However, oral administration contributes to lower

adherence rates with these drugs. In the United States and Europe,